報價延遲最少15分鐘:2025/06/04 03:40 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.14/0.69
|
|
企業價值
6.19B
|
| 資產負債 |
|
每股賬面淨值
1.09
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
783.21M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 03:40 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer. |